CDKN2A and cancer: Given the similarity of AP-1 and AP-2 DNA binding domains and their recognized DNA sequence homology [57], it is likely both transcription factors can fulfill similar, but unique, functional roles in mediating acquired cetuximab resistance in HNSCC cells with low CDKN2A expression and other cancers treated with EGFR inhibitors.